Status:
COMPLETED
Prospective Minnesota Study of ECHO Tissue Doppler Imaging in Cardiac Resynchronization Therapy
Lead Sponsor:
Hennepin Healthcare Research Institute
Collaborating Sponsors:
Guidant Corporation
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess whether tissue doppler imaging is useful in predicting which patients will respond most to Cardiac Resynchronization therapy ( a type of pacemaker)
Detailed Description
Cardiac Resynchronization Therapy (CRT) is a newly developed therapy designed to improve outcomes in patients with heart failure(HF). Recent studies have shown significant symptomatic improvement and ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Moderate or severe heart failure defined as NYHA class III-IV despite optimal pharmacological heart failure therapy.
- Stable Heart failure as defined as not hospitalized within the last month. A 12 lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a sinus rate \>50bpm, QRS duration \>120ms and PR interval\> 150ms Ejection Fraction \<35% documented within the last 6 months by one of the following methods: echo ( standard or TEE) LV gram, or MUGA Clinically indicated to receive CRT Ability to complete all the study visits including geographic stability
- Exclusion criteria:
- Serum creatinine \>3.5 Have or had a Myocardial infarct, unstable angina, percutaneous coronary intervention or coronary artery bypass graft during the preceding 30 days prior to enrollment.
- Have had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement.
- Dyspnea believed by the physician to be primarily related to lung disease. Have an atrial tachyarrhythmia that is permanent ( ie does not terminate spontaneously and cannot be terminated with medical intervention)or persistent (can be terminated with medical intervention but does not terminate spontaneously)within 90 days prior to enrollment Poor sinus node function that MD predicts will require \>70% atrial pacing. Inability to perform the six minute walk. Life expectancy of less than 6 months due to other medical conditions or expected to undergo heart transplant within the next 6 months.
- Have a mechanical tricuspid heart valve. Hypertrophic obstructive cardiomyopathy. Patients with a hypersensitivity to a 0.7mg nominal dose of dexamethasone. Surgically uncorrected primary valvular heart disease. Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study.
- Patients who are younger than 18 years of age, pregnant, or who are mentally incompetent and cannot sign a patient informed consent.
- \-
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00158015
Start Date
October 1 2004
End Date
September 1 2007
Last Update
October 4 2012
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Metropolitan Cardiology consultants
Coon Rapids, Minnesota, United States, 55433
2
Minnesota Heart Clinic
Edina, Minnesota, United States, 55417
3
Minneapolis Heart Institute
Minneapolis, Minnesota, United States, 55407
4
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415